Travere Therapeutics, Inc. (NASDAQ:TVTX) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On ...

If approved, sparsentan will be a first-in-class treatment to address the significant unmet medical need in IgA nephropathy (IgAN) in Europe SAN DIEGO and ST. GALLEN, Switzerland, Aug. 22, 2022 ...

Travere Therapeutics will host a conference call and webcast today, Thursday, September 5, 2024 at 6 p.m. ET to discuss the FDA full approval of FILSPARI.

S hares of IBD 50 stock Travere Therapeutics plummeted Friday after the Food and Drug Administration accepted its review application for a rare kidney disease drug — with one caveat.

Travere Therapeutics (TVTX) shares soared 11.6% in the last trading session to close at $15.23. The move was backed by solid volume with far more shares changing hands than in a normal session.

SAN DIEGO, June 11, 2025--Travere Therapeutics today announced that the Company will present three abstracts at the upcoming International Podocyte Conference.

Travere also has a partner in Japan, Renalys Pharma, conducting Phase 3 studies of the drug in the region. With that said, in 2024 drug approval catalysts have not always played out positively, ...

SAN DIEGO, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced a voluntary pause of enrollment in the Phase 3 HARMONY Study evaluating pegtibatinase for ...

Travere Therapeutics Inc has a consensus price target of $32.53 based on the ratings of 21 analysts. The high is $47 issued by Guggenheim on April 14, 2025.The low is $11 issued by Piper Sandler ...

FDA approves expanded indication making FILSPARI available to patients with IgA nephropathy (IgAN) at risk of progression; updated label includes data showing long-term durable benefit on ...